Prescription drug laws, drug overdoses, and drug sales in New York and Pennsylvania
- 122 Downloads
Drug overdose mortality nearly doubled in the United States from 1999 to 2004, with most of the increase due to prescription drug overdoses. Studying mortality rates in states that did not experience such increases may identify successful prescription overdose prevention strategies. We compared New York, a state that did not experience an overdose increase, with its neighbor, Pennsylvania. New York and Pennsylvania had prescription drug monitoring programs (PDMPs), but New York's PDMP was better funded and made use of serialized, tamperproof prescription forms. Per capita usage of the major prescription opioids in New York was two-thirds that of Pennsylvania. The drug overdose death rate in Pennsylvania was 1.6 times that of New York in 2006. Differences between New York and Pennsylvania might be due to the regulatory environment in New York State.
Keywordsopioid overdose regulation drug abuse poisoning mortality
Special thanks to those who contributed information about their state laws and programs: Jennifer Treacy in New York and Lawrence Cherba in Pennsylvania; also to John Eadie for his helpful comments on an earlier version of this article.
- Centers for Disease Control and Prevention. WONDER [Online]. (2009) Centers for Disease Control and Prevention (producer), http://wonder.cdc.gov, accessed 21 August 2009.
- Fingerhut, L.A. and Anderson, R.N. (2008) The Three Leading Causes of Injury Mortality in the United States, 1999–2005. Hyattsville, MD: National Center for Health Statistics.Google Scholar
- Paulozzi, L.J. and Annest, J.L. (2007) Unintentional poisoning deaths – United States, 1999–2004. Morbidity and Mortality Weekly Report 56: 93–96.Google Scholar
- Controlled Substances Act, 21 USC 801 et seq 2002. (GENERIC).Google Scholar
- US General Accounting Office. (2002) Prescription Drugs: State Monitoring Programs Provide Useful Tool to Reduce Diversion. Washington DC: US General Accounting Office, Report No. GAO-02-634.Google Scholar
- US Department of Justice Drug Enforcement Administration. (2008) Prescription drug monitoring programs, http://www.deadiversion.usdoj.gov/faq/rx_monitor.htm, accessed 15 October 2008.
- National Alliance for Model State Drug Laws. (2010) Prescription drug monitoring project, http://www.namsdl.org, accessed 10 May 2010.
- US Department of Commerce Census Bureau. (2006) 2000 Census, Summary File 3, Table P.5 urban and rural, http://www.census.gov/prod/cen2000/doc/sf1.pdf, accessed 15 December 2006.
- US Department of Justice (USDOJ) Drug Enforcement Administration. (2009) ARCOS: Automation of reports and consolidated orders system, http://www.deadiversion.usdoj.gov/arcos/index.html, accessed 27 March 2009.
- Substance Abuse and Mental Health Services Administration. (2009) Drug Abuse Warning Network, 2007: Area Profiles of Drug-Related Mortality. Rockville, MD: SAMHSA.Google Scholar
- Office of the Inspector General. (1992) Multiple Copy Prescription Programs: State Experiences. Washington DC: Department of Health and Human Services, Report No. OEI-12-91-00490.Google Scholar
- Bishop, M.T. and Vlasty, R.J. (1993) The Illinois experience in achieving the medical/regulatory balance required to control prescription drug diversion. NIDA Research Monographs, 131, pp. 159–175.Google Scholar
- Ross-Degnan, D., Simoni-Wastila, L., Brown, J.F., Gao, X., Mah, C. and Cosler, L.E. et al (2004) A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a Medicaid population. International Journal of Psychiatry in Medicine 34 (2): 103–123.CrossRefGoogle Scholar
- New York State Department of Health. (2010) State prescription forms reducing fraud and abuse, http://www.health.state.ny.us/press/releases/2007/2007-07-31_prescription_fraud_savings.htm, accessed 10 May 2010.
- Bolen, J. (2010) State opioid prescribing policy: New Jersey, http://www.medscape.com/resource/opioid/opioid-newjersey, accessed 17 May 2010.
- Lambert, D. (2010) Impact evaluation of Maine's prescription drug monitoring program, http://www.maine.gov/dhhs/osa/data/pmp/files/Reports/PMP_EVALUATION_REPORT_4-06.htm, accessed 10 May 2010.
- Forgione, D.A., Neuenschwander, P. and Vermeer, T.E. (2001) Diversion of prescription drugs to the black market: What the states are doing to curb the tide. Journal of Health Care Finance 27 (4): 65–78.Google Scholar
- Tonry, M. (1996) Sentencing Matters. New York: Oxford University Press.Google Scholar